Jin Medicine Industry (600488.SH): Dibutyl phthalate beclomethasone raw material drug obtains FDA DMF FA Letter.

Financial news through the Wise Finance APP, Jin Medicine Industry (600488.SH) announced that recently, the company has received the DMF First Adequate Letter (DMF FA Letter) issued by the Food and Drug Administration (FDA) of the United States, indicating that the FDA has completed the scientific review of the company's dexamethasone dipropionate raw material DMF file, which can meet the ANDA application requirements of related formulation customers.